GW873140 In Combination With Kaletra In HIV Infected Subjects
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 175
- Registration Number
- NCT00102778
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 474
- Registration Number
- NCT00098722
- Locations
- 🇬🇧
Pfizer Investigational Site, Newcastle Upon Tyre, United Kingdom
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 190
- Registration Number
- NCT00098748
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-07
- Last Posted Date
- 2013-10-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 916
- Registration Number
- NCT00098293
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-07
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 601
- Registration Number
- NCT00098306
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Fosamprenavir Versus Other Protease Inhibitors
- First Posted Date
- 2004-10-21
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 314
- Registration Number
- NCT00094523
- Locations
- 🇵🇷
GSK Investigational Site, Ponce, Puerto Rico
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-08-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 110
- Registration Number
- NCT00089583
- Locations
- 🇪🇸
GSK Investigational Site, Vigo ( Pontevedra), Spain
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 59
- Registration Number
- NCT00071760
- Locations
- 🇿🇦
GSK Investigational Site, Soweto, South Africa
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 240
- Registration Number
- NCT00046176
- Locations
- 🇵🇷
GSK Investigational Site, Rio Piedras, Puerto Rico
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 166
- Registration Number
- NCT00044577
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath